Stockscreener 앱 받기
0.6453
1.37%
-0.00418
Longeveron Inc 주식(LGVN)의 최신 뉴스
symbol__ Stock Quote Price and Forecast - CNN
Longeveron names Marie Washburn as CFO - MSN
Form 4 Longeveron LLC For: 6 July By Investing.com - Investing.com Canada
Longeveron (NASDAQ: LGVN) CTO has 15,808 shares withheld for taxes - Stock Titan
Longeveron (LGVN) CFO has shares withheld to cover RSU tax obligations - Stock Titan
Longeveron (LGVN) CMO reports 22,505-share tax withholding after RSU vesting - Stock Titan
Longeveron strengthens financial leadership with new CFO appointment - TipRanks
Longeveron Appoints Marie Washburn as Chief Financial Officer - citybiz
New Longeveron (NASDAQ: LGVN) CFO and reverse stock split approval - Stock Titan
Longeveron taps Marie Washburn as CFO ahead of July trial readout - Stock Titan
Price to sales forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Enterprise value to revenue forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Enterprise value to EBITDA forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Price to earnings forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - The National Law Review
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - The National Law Review
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron Inc. Class A Actuals & Estimates (NASDAQ:LGVN) - TradingView
LGVN Forecast — Price Target — Prediction for 2027 - TradingView
LGVN News | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
Longeveron Inc (LGVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Longeveron’s Alzheimer’s trial data accepted for poster presentation - Investing.com UK
Longeveron’s Alzheimer’s trial data accepted for poster presentation By Investing.com - Investing.com South Africa
Longeveron to Present Additional Phase 2a Laromestrocel Data in Mild Alzheimer’s Disease at AAIC 2026 - Quiver Quantitative
Longeveron gets AAIC poster slot for Alzheimer’s stem cell data - Stock Titan
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) - The Manila Times
Longeveron Inc (LGVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Longeveron Inc (LGVN) Institutional Confidence - TradingKey
Longeveron Inc (LGVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Longeveron Inc (LGVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Longeveron Inc (LGVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Longeveron Inc (LGVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Longeveron Inc (LGVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Longeveron Inc (LGVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Longeveron receives SME status from European regulator By Investing.com - Investing.com Nigeria
Longeveron receives SME status from European regulator - Investing.com UK
Longeveron Granted SME Status by European Medicines Agency - Moomoo
Longeveron Inc. Awarded SME Status by European Medicines Agency, Enhancing Drug Development Opportunities - Quiver Quantitative
Biotech Longeveron wins EMA SME status, where SME drugs saw 89% OKs - Stock Titan
Number of shareholders of Longeveron Inc. – BOATS:LGVN - TradingView
LGVN Q1 2026 Earnings: Deeper Losses Weigh on Shares as Clinical Progress ContinuesGross Profit Margin - newsline.com
Longeveron Announces CFO Transition to Internal Successor - TipRanks
LongeveronOn June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026SEC Filing - TradingView
Longeveron (NASDAQ: LGVN) CFO Lisa Locklear to step down, controller eyed as successor - Stock Titan
Longeveron to Present at BIO International Convention 2026 - BioSpace
LGVN Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D AdvancesCapex Guidance - newsline.com
LGVN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Clinical-Stage Biotech Navigates Costs - newsline.com
Longeveron Inc. (LGVN) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEarnings Trend Analysis - The Legal Advocate
Longeveron (LGVN) Stock Forecast & Analyst Ratings - Moomoo
LGVNLongeveron Inc Stock Price and Quote - Finviz
LGVN | Longeveron Inc. Common Stock Executive Compensation - Quiver Quantitative
Longeveron Inc. Q1 2026 Earnings: EPS Misses Estimates Despite Stock RallyRevenue Growth Report - dars.gov.et
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design - MSN
LGVN Should I Buy - Intellectia AI
Longeveron CEO outlines strategy ahead of August trial data - Investing.com India
Longeveron CEO outlines strategy ahead of August trial data By Investing.com - Investing.com Nigeria
Longeveron Inc. (LGVN) Edges Higher Amid Stabilization at $0.72Dividend Growth Stocks - The Legal Advocate
1.16%
0.48%
자본화:
|
볼륨(24시간):